Treatment with Mycophenolat Mofetil of Steroid-Dependent Asthma—One Case of Severe Asthma

Backer, Vibeke; Hjardem, Elisabeth; Karlsmark, Tonny

doi:10.1155/2009/821013

Cited by 2 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The application of MMF for patients with severe therapy-resistant asthma was described in a case study of 22 patients in which more than half of the patients benefitted from the treatment [126]. In an earlier study, the successful treatment of a patient suffering from non-allergic, therapy-resistant asthma with MMF had been reported [127]. Also, for severe cases of atopic dermatitis, which were not adequately controlled by topical treatment, MMF was successfully applied [128].…”

Section: Mycophenolate Mofetil-mycophenolate Mofetil (Mmf)mentioning

confidence: 99%

Pharmacological targeting of allergen-specific T lymphocytes

Tauber

Pickl

2017

Immunology Letters

View full text Add to dashboard Cite

Allergic disorders are the result of a complex pathophysiology, involving major cellular lineages and a multitude of humoral factors of the innate and adaptive immune system, and have the tendency to involve multiple organs. Consequently, even standard pharmacological treatment of allergies is rarely specific but usually targets more than one pathway/cellular system at a time. Accordingly, many of the classic anti-allergic drugs have a critical impact also on T helper cells, which are pivotal not only during the sensitization but also the maintenance phase of allergic diseases. Recent years have seen a dramatic increase of novel drugs with the potency to interfere, more or less specifically, with T lymphocyte function, which might, possibly together with classic anti-allergic drugs, help harnessing one of the central cellular players in allergic responses. A major theme in the years to come will be a thoughtful combination of previously established with recently developed treatment modalities.

show abstract

Section: Mycophenolate Mofetil-mycophenolate Mofetil (Mmf)mentioning

confidence: 99%

Pharmacological targeting of allergen-specific T lymphocytes

Tauber

Pickl

2017

Immunology Letters

View full text Add to dashboard Cite

show abstract

“…16 To emphasize this relationship, the KEGG pathway has05310 (asthma) is significantly enriched directly in genes of the MMF molecular footprint. So far MMF has not been commonly considered in inflammatory respiratory diseases although recently its beneficial role and future clinical studies have been suggested based on success in a patient with treatment resistant severe non-allergic asthma, 43 an effect probably based on reduced bone marrow eosinophilopoiesis. 44 The next group of drugs is constituted by a number of Ca + + transporting ATPase (ATP2C1) targeting, inhaled anesthetics including isoflurane, desflurane, methoxyflurane, enflurane and sevoflurane.…”

Section: Drug Targets Linked To Mmf In Explicit Synthetic Lethal Inte...mentioning

confidence: 99%

Synthetic lethality for linking the mycophenolate mofetil mode of action with molecular disease and drug profiles

et al. 2012

View full text Add to dashboard Cite

Systematic study of the effect of mycophenolate mofetil (MMF) on the molecular level in the context of other drugs and molecular disease profiles became possible due to the availability of large scale molecular profiles on both disease characterization and drug mode of action. Such analysis is of particular value in elucidating alternative drug use for addressing clinically unmet needs, and the concept of synthetic lethality provides an alternative tool for such repositioning strategies. Resting on consolidation of transcriptomics data and literature mining, a MMF molecular footprint became available including a set of 170 genes specifically affected by the drug. Analysis of this profile on a molecular pathway level reveals a set of 14 pathways as affected. Next to assignment of molecular pathways and associated diseases synergistic drug combinations are proposed by utilizing the synthetic lethal interaction network. Of particular interest is the combination of MMF with adenosine deaminase inhibitors, sulfasalazine, and other selected drugs interfering with calcium-based regulatory pathways and metabolism. Indeed analysis of drugs in clinical trials positively identifies combinations with MMF in the context of synthetic lethality and affected pathways, particularly in diseases such as multiple sclerosis, vasculitis, GVHD and lupus nephritis. Importantly, the synthetic lethal interaction of the drug mode of action is an interesting basis for rational repositioning strategies by suggesting combinations which exhibit a synergistic rather than a mere additive effect, as for example is evident for the combination of tacrolimus and MMF. Inherent is also the assessment of possible adverse effects of drug combinations.

show abstract

“…This represents the largest case series of MMF in treatment-resistant asthma. There has only been one previous single case report [4] and a report of beneficial experience in a Churg-Strauss-like syndrome [5].…”

mentioning

confidence: 99%

“…Total IgE was 2048 kU?L -1 , white blood cell count 7.81610 9 L -1 and eosinophil count was raised at 0.75610 9 L -1 . Two-hourly peak flow measurements made at home and work over 4 weeks were analysed using OASYS [3,4]. The OASYS score was 3.4 and the area between the curves score was 23.4 L?min -1 ?h -1 confirming a significant work effect ( fig.…”

mentioning

confidence: 99%